1. Scrip
  2. >>Focus On Asia

Glenmark’s Remogliflozin Hopes To Shake Up Indian SGLT2i Market

 
• By Anju Ghangurde

Glenmark’s remogliflozin is priced about 50% lower than the other SGLT2 inhibitors in India and is expected to expand access to the class of drugs significantly. Early physician outlook for the new SGLT2 inhibitor appears encouraging.

Diabetes
GLENMARK HAS LAUNCHED A NOVEL SGLT2 Inhibitor

Glenmark Pharmaceuticals Ltd.’s teneligliptin effectively changed market dynamics in the Indian gliptins segment in 2015 when it made a debut at a price that was 55% lower than the other DPP4 inhibitors at the time – teneligliptin volumes have since surged, overshadowing peers in the class. And the Mumbai-based company now appears to be hoping for a similar run with another diabetes therapy, remogliflozin etabonate, that has hit the Indian market backed by an aggressive cut-price approach.

Glenmark's novel sodium glucose co-transporter-2 (SGLT2) inhibitor, remogliflozin (marketed as Remo and Remozen), comes at a daily treatment cost of INR25 ($0.36; 12

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.